

Alan D Michelson

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3231694/publications.pdf>

Version: 2024-02-01

281
papers

19,121
citations

10389

72
h-index

12946

131
g-index

290
all docs

290
docs citations

290
times ranked

13672
citing authors

#	ARTICLE	IF	CITATIONS
1	Platelet surface GPIb β , activated GPIIb-IIIa, and <i>P</i> -selectin levels in adult veno-arterial extracorporeal membrane oxygenation patients. <i>Platelets</i> , 2022, 33, 116-122.	2.3	5
2	Dosing Regimen Prediction and Confirmation With Rivaroxaban for Thromboprophylaxis in Children After the Fontan Procedure: Insights From the Phase III UNIVERSE Study. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 220-231.	2.0	7
3	Inhibition of transcription factor NFAT activity in activated platelets enhances their aggregation and exacerbates gram-negative bacterial septicemia. <i>Immunity</i> , 2022, 55, 224-236.e5.	14.3	11
4	Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 675-681.	2.1	9
5	Evaluation of Longitudinal Pain Study in Sickle Cell Disease (ELIPSIS) by patient-reported outcomes, actigraphy, and biomarkers. <i>Blood</i> , 2021, 137, 2010-2020.	1.4	21
6	Platelet mass cytometry: Optimization of sample, reagent, and analysis parameters. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 170-179.	1.5	11
7	Decreased platelet surface phosphatidylserine predicts increased bleeding in patients with severe factor VIII deficiency. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 976-982.	3.8	3
8	Familial thrombocytopenia due to a complex structural variant resulting in a <i>WAC-ANKRD26</i> fusion transcript. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	20
9	Activation of platelet-rich plasma by pulse electric fields: Voltage, pulse width and calcium concentration can be used to control and tune the release of growth factors, serotonin and hemoglobin. <i>PLoS ONE</i> , 2021, 16, e0249209.	2.5	3
10	Platelet Immunophenotyping by High-Dimensional Mass Cytometry. <i>Current Protocols</i> , 2021, 1, e112.	2.9	5
11	Immunophenotypic Analysis of Platelets by Flow Cytometry. <i>Current Protocols</i> , 2021, 1, e178.	2.9	10
12	Consensus recommendations on flow cytometry for the assessment of inherited and acquired disorders of platelet number and function: Communication from the ISTH SSC Subcommittee on Platelet Physiology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 3193-3202.	3.8	20
13	Platelet activation and reactivity in a large cohort of patients with Gaucher disease. <i>Thrombosis and Haemostasis</i> , 2021, 0, .	3.4	4
14	Thromboprophylaxis for Children Post-Fontan Procedure: Insights From the UNIVERSE Study. <i>Journal of the American Heart Association</i> , 2021, 10, e021765.	3.7	32
15	Real-World Anticoagulant Use and Incidence of Venous Thromboembolism and Major Bleeding in Children. <i>Clinical Therapeutics</i> , 2021, 43, 2074-2087.	2.5	4
16	Sex-specific platelet activation through protease-activated receptor-1 in patients undergoing cardiac catheterization. <i>Atherosclerosis</i> , 2021, 339, 12-19.	0.8	4
17	An exploratory, randomised, placebo-controlled, 14-day trial of the soluble guanylate cyclase stimulator praliguat in participants with type 2 diabetes and hypertension. <i>Diabetologia</i> , 2020, 63, 733-743.	6.3	21
18	Changes in neurocognitive function and central nervous system structure in childhood acute lymphoblastic leukaemia survivors after treatment: a meta-analysis. <i>British Journal of Haematology</i> , 2020, 188, 945-961.	2.5	21

#	ARTICLE	IF	CITATIONS
19	Illustrated State-of-the-Art Capsules of the ISTH 2020 Congress. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 680-713.	2.3	3
20	Novel manifestations of immune dysregulation and granule defects in gray platelet syndrome. Blood, 2020, 136, 1956-1967.	1.4	34
21	Novel Antiplatelet Agents in Cardiovascular Disease. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 191-200.	2.0	28
22	Usefulness of anti-platelet therapy testing in children supported with a ventricular assist device. Journal of Heart and Lung Transplantation, 2019, 38, 781-783.	0.6	3
23	Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3). Contemporary Clinical Trials, 2019, 85, 105835.	1.8	6
24	Rivaroxaban, a direct Factor Xa inhibitor, versus acetylsalicylic acid as thromboprophylaxis in children post-Fontan procedure: Rationale and design of a prospective, randomized trial (the Tj ETQq0 0 0 rgBT4 Overlock20 Tf 50 5	1.0	26
25	Laboratory Monitoring of Antiplatelet Therapy. , 2019, , 653-682.		0
26	Antiplatelet Drugs in the Management of Thrombotic/Ischemic Events in Children. , 2019, , 1079-1083.		4
27	Using extracellular calcium concentration and electric pulse conditions to tune platelet-rich plasma growth factor release and clotting. Medical Hypotheses, 2019, 125, 100-105.	1.5	13
28	<sc>PF</sc>â€œ04447943, a Phosphodiesterase 9A Inhibitor, in Stable Sickle Cell Disease Patients: A Phase Ib Randomized, Placeboâ€œControlled Study. Clinical and Translational Science, 2019, 12, 180-188.	3.1	25
29	Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor: reply. Journal of Thrombosis and Haemostasis, 2018, 16, 607-608.	3.8	1
30	Platelet Function in ITP, Independent of Platelet Count, Is Consistent Over Time and Is Associated with Both Current and Subsequent Bleeding Severity. Thrombosis and Haemostasis, 2018, 118, 143-151.	3.4	41
31	Immature platelet fraction in immune thrombocytopenia: Useful in diagnosis but does it predict bleeding?. Pediatric Blood and Cancer, 2018, 65, e26842.	1.5	4
32	HanÃ¶daga:yas (Town Destroyer) and Mantle. Third Text, 2018, 32, 689-692.	0.4	0
33	Tunable activation of therapeutic platelet-rich plasma by pulse electric field: Differential effects on clot formation, growth factor release, and platelet morphology. PLoS ONE, 2018, 13, e0203557.	2.5	9
34	Avatrombopag increases platelet count but not platelet activation in patients with thrombocytopenia resulting from liver disease. Journal of Thrombosis and Haemostasis, 2018, 16, 2515-2519.	3.8	31
35	GLS-409, an Antagonist of Both P2Y1 and P2Y12, Potently Inhibits Canine Coronary Artery Thrombosis and Reversibly Inhibits Human Platelet Activation. Scientific Reports, 2018, 8, 14529.	3.3	5
36	Novel aspects of antiplatelet therapy in cardiovascular disease. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 439-449.	2.3	41

#	ARTICLE	IF	CITATIONS
37	Mass Cytometry Reveals Distinct Platelet Subtypes in Healthy Subjects and Novel Alterations in Surface Glycoproteins in Glanzmann Thrombasthenia. <i>Scientific Reports</i> , 2018, 8, 10300.	3.3	49
38	Synergistic Platelet Inhibitory Effects of Riociguat and Nitric Oxide Are Decreased By Protein Binding. <i>Blood</i> , 2018, 132, 4971-4971.	1.4	0
39	Incomplete reversibility of platelet inhibition following prolonged exposure to ticagrelor. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 858-867.	3.8	11
40	How I use laboratory monitoring of antiplatelet therapy. <i>Blood</i> , 2017, 130, 713-721.	1.4	42
41	High serum serotonin in sudden infant death syndrome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 7695-7700.	7.1	52
42	GLS-409, a Synergistic Inhibitor of Both P2Y1 and P2Y12: Efficacy in a Canine Model of Recurrent Coronary Thrombosis and Reversibility of Human Platelet Inhibition. <i>Blood</i> , 2017, 130, 630-630.	1.4	1
43	A Phase 1b, Randomized, Double-Blind, Placebo-Controlled Study of PF-04447943 in Patients with Stable Sickle Cell Disease: Changes in Exploratory Biomarkers. <i>Blood</i> , 2017, 130, 974-974.	1.4	23
44	Platelet-rich plasma stimulated by pulse electric fields: Platelet activation, procoagulant markers, growth factor release and cell proliferation. <i>Platelets</i> , 2016, 27, 1-8.	2.3	33
45	Assessment of whole blood thrombosis in a microfluidic device lined by fixed human endothelium. <i>Biomedical Microdevices</i> , 2016, 18, 73.	2.8	101
46	Whole Blood Analysis of Leukocyte-Platelet Aggregates. <i>Current Protocols in Cytometry</i> , 2016, 78, 6.15.1-6.15.10.	3.7	19
47	Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. <i>Thrombosis and Haemostasis</i> , 2016, 116, 69-77.	3.4	19
48	Synergistic Inhibition of Both P2Y ₁ and P2Y ₁₂ Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 501-509.	2.4	49
49	New highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptors. <i>European Journal of Medicinal Chemistry</i> , 2016, 107, 204-218.	5.5	35
50	In Vivo and protease-activated receptor-1-mediated platelet activation in patients presenting for cardiac catheterization. <i>Platelets</i> , 2016, 27, 308-316.	2.3	6
51	Platelet Physiology. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 191-204.	2.7	233
52	Aspirin response: Differences in serum thromboxane B2 levels between clinical studies. <i>Platelets</i> , 2016, 27, 196-202.	2.3	10
53	Modification of Pulsed Electric Field Conditions Results in Distinct Activation Profiles of Platelet-Rich Plasma. <i>PLoS ONE</i> , 2016, 11, e0160933.	2.5	22
54	The Platelet Phenotype of Children with ITP Is Consistent over Time and Is Associated with Both Concurrent and Subsequent Bleeding Severity. <i>Blood</i> , 2016, 128, 2550-2550.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopenia. <i>Blood</i> , 2015, 126, 1367-1378.	1.4	82
56	Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. <i>Blood</i> , 2015, 126, 873-879.	1.4	124
57	Platelet geometry sensing spatially regulates α -granule secretion to enable matrix self-deposition. <i>Blood</i> , 2015, 126, 531-538.	1.4	38
58	Do immature platelet levels in chest pain patients presenting to the emergency department aid in the diagnosis of acute coronary syndrome?. <i>International Journal of Laboratory Hematology</i> , 2015, 37, 112-119.	1.3	19
59	Soluble CD40 Ligand in Aspirin-Treated Patients Undergoing Cardiac Catheterization. <i>PLoS ONE</i> , 2015, 10, e0134599.	2.5	11
60	Point-of-care assessment of platelet reactivity in the emergency department may facilitate rapid rule-out of acute coronary syndromes: a prospective cohort pilot feasibility study. <i>BMJ Open</i> , 2014, 4, e003883.	1.9	7
61	Platelet activation using electric pulse stimulation. <i>Journal of Trauma and Acute Care Surgery</i> , 2014, 77, S94-S100.	2.1	25
62	Challenges and Priorities for Research. <i>Circulation</i> , 2014, 130, 1192-1203.	1.6	28
63	Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 2-13.	3.8	50
64	Variability of Individual Platelet Reactivity Over Time in Patients Treated With Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2014, 64, 361-368.	2.8	70
65	Platelet Activation and Inhibition in Sickle cell disease (PAINS) study. <i>Platelets</i> , 2014, 25, 27-35.	2.3	47
66	Antiplatelet Activity, P2Y1 and P2Y12 Inhibition, and Metabolism in Plasma of Stereoisomers of Diadenosine 5',5'-P1,P4-dithio-P2,P3-chloromethylenetetraphosphate. <i>PLoS ONE</i> , 2014, 9, e94780.	2.5	7
67	Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including) Tj ETQq1 1 0.784314 μ gBT /Ov <i>College of Cardiology</i> , 2013, 61, 872-879.	2.8	170
68	Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia: a reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1002-1003.	3.8	3
69	The aryl hydrocarbon receptor directs hematopoietic progenitor cell expansion and differentiation. <i>Blood</i> , 2013, 122, 376-385.	1.4	119
70	P2Y ₁₂ Receptor Blockade Augments Glycoprotein IIb/IIIa Antagonist Inhibition of Platelet Activation, Aggregation, and Procoagulant Activity. <i>Journal of the American Heart Association</i> , 2013, 2, e000026.	3.7	15
71	Clinical and Laboratory Significance of Defective P2Y12 Pathway Function in Patients with Myeloproliferative Neoplasms: A Pilot Study. <i>Acta Haematologica</i> , 2013, 130, 181-187.	1.4	4
72	Recommendations for the standardization of light transmission aggregometry: a consensus of the working party from the platelet physiology subcommittee of SSC/ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1183-1189.	3.8	398

#	ARTICLE	IF	CITATIONS
73	Gray platelet syndrome. <i>Blood</i> , 2013, 121, 250-250.	1.4	5
74	Association Of Platelet Function Markers, Independent Of Platelet Count, With Bleeding Score In Patients With Immune Thrombocytopenia. <i>Blood</i> , 2013, 122, 3534-3534.	1.4	0
75	Effects Of Eltrombopag On Thrombocytopenia, Platelet Function and Bleeding In Patients With Wiskott-Aldrich Syndrome/X-Linked Thrombocytopenia. <i>Blood</i> , 2013, 122, 3536-3536.	1.4	0
76	Pharmacodynamic effects of clopidogrel in pediatric cardiac patients: A comparative study of platelet aggregation response. <i>Platelets</i> , 2012, 23, 430-438.	2.3	10
77	Granule exocytosis is required for platelet spreading: differential sorting of α -granules expressing VAMP-7. <i>Blood</i> , 2012, 120, 199-206.	1.4	86
78	In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation. <i>Blood</i> , 2012, 119, 4066-4072.	1.4	86
79	Modified diadenosine tetraphosphates with dual specificity for P2Y1 and P2Y12 are potent antagonists of ADP-induced platelet activation. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2573-2580.	3.8	15
80	A Randomized, 2-Period, Crossover Design Study to Assess the Effects of Dexlansoprazole, Lansoprazole, Esomeprazole, and Omeprazole on the Steady-State Pharmacokinetics and Pharmacodynamics of Clopidogrel in Healthy Volunteers. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1304-1311.	2.8	120
81	Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Non-Compliance, Diet, Smoking, Co-Medications (including) Tj ETQq1 1i04784314rgBT /O		
82	Platelet Activation and Inhibition in Sickle Cell Disease (PAINS) Study. <i>Blood</i> , 2012, 120, 5147-5147.	1.4	0
83	Intrinsic platelet reactivity before P2Y12 blockade contributes to residual platelet reactivity despite high-level P2Y12 blockade by prasugrel or high-dose clopidogrel. <i>Thrombosis and Haemostasis</i> , 2011, 106, 219-226.	3.4	48
84	A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes Mellitus (OPTIMUS)-3 Trial. <i>European Heart Journal</i> , 2011, 32, 838-846.	2.2	178
85	The Influence of Intermittent Hypoxemia on Platelet Activation in Obese Patients with Obstructive Sleep Apnea. <i>Journal of Clinical Sleep Medicine</i> , 2011, 07, 172-178.	2.6	48
86	The Human Endogenous Circadian System Causes Greatest Platelet Activation during the Biological Morning Independent of Behaviors. <i>PLoS ONE</i> , 2011, 6, e24549.	2.5	153
87	Advances in Antiplatelet Therapy. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 62-69.	2.5	33
88	Effects of in vitro adult platelet transfusions on neonatal hemostasis. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 1020-1028.	3.8	57
89	Differences in platelet function in patients with acute myeloid leukemia and myelodysplasia compared to equally thrombocytopenic patients with immune thrombocytopenia. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 2302-2310.	3.8	108
90	Hormonal Contraception and Thrombotic Risk: A Multidisciplinary Approach. <i>Pediatrics</i> , 2011, 127, 347-357.	2.1	90

#	ARTICLE	IF	CITATIONS
91	Dosing Clopidogrel Based on CYP2C19 Genotype and the Effect on Platelet Reactivity in Patients With Stable Cardiovascular Disease. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 2221-8.	7.4	313
92	In Vivo Platelet Activation and Its In Vitro Inhibition by Prasugrel's Active Metabolite In Adolescents with Sickle Cell Disease. <i>Blood</i> , 2011, 118, 2141-2141.	1.4	0
93	The influence of intermittent hypoxemia on platelet activation in obese patients with obstructive sleep apnea. <i>Journal of Clinical Sleep Medicine</i> , 2011, 7, 172-8.	2.6	30
94	Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 331-340.	3.8	51
95	Antiplatelet therapies for the treatment of cardiovascular disease. <i>Nature Reviews Drug Discovery</i> , 2010, 9, 154-169.	46.4	329
96	Response to Letter Regarding Article, "Association of Cyclooxygenase-1-Dependent and -Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization". <i>Circulation</i> , 2010, 122, .	1.6	0
97	The Platelet Activity After Clopidogrel Termination (PACT) Study. <i>Circulation: Cardiovascular Interventions</i> , 2010, 3, 442-449.	3.9	34
98	Soluble CD40 ligand is elevated in Type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function. <i>Platelets</i> , 2010, 21, 525-532.	2.3	30
99	Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. <i>Thrombosis Research</i> , 2010, 125, 159-165.	1.7	81
100	Thrombophilia and Pediatric Stroke. <i>Circulation</i> , 2010, 121, 1795-1797.	1.6	17
101	Association of Cyclooxygenase-1-Dependent and -Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization. <i>Circulation</i> , 2009, 120, 2586-2596.	1.6	168
102	Methods for the Measurement of Platelet Function. <i>American Journal of Cardiology</i> , 2009, 103, 20A-26A.	1.6	235
103	Platelet reactivity and the identification of acute coronary syndromes in the emergency department. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 31-37.	2.1	4
104	Results of a worldwide survey on the assessment of platelet function by light transmission aggregometry: a report from the platelet physiology subcommittee of the SSC of the ISTH. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1029.	3.8	177
105	The platelet hyporeactivity of extremely low birth weight neonates is age-dependent. <i>Thrombosis Research</i> , 2009, 124, 42-45.	1.7	86
106	Nephropathy in Type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity. <i>Platelets</i> , 2009, 20, 513-519.	2.3	28
107	Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. <i>Lancet</i> , The, 2009, 374, 989-997.	13.7	650
108	New P2Y12 antagonists. <i>Current Opinion in Hematology</i> , 2009, 16, 371-377.	2.5	28

#	ARTICLE	IF	CITATIONS
109	Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. <i>European Heart Journal</i> , 2009, 30, 1753-1763.	2.2	226
110	The Role of Platelet Function Testing in the Development of Platelet Inhibitors. <i>Fundamental and Clinical Cardiology</i> , 2009, , 99-116.	0.0	0
111	Clinical Considerations with the Use of Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2008, 31, 128-135.	1.8	2
112	Investigating the Mechanisms of Hyporesponse to Antiplatelet Approaches. <i>Clinical Cardiology</i> , 2008, 31, 121-127.	1.8	7
113	Assessing the Current Role of Platelet Function Testing. <i>Clinical Cardiology</i> , 2008, 31, 110-116.	1.8	26
114	Antiplatelet Strategies: Evaluating Their Current Role in the Setting of Acute Coronary Syndromes. <i>Clinical Cardiology</i> , 2008, 31, 12-19.	1.8	9
115	The Problem of Persistent Platelet Activation in Acute Coronary Syndromes and Following Percutaneous Coronary Intervention. <i>Clinical Cardiology</i> , 2008, 31, 117-120.	1.8	33
116	Antiplatelet Therapy and Platelet Function Testing. <i>Clinical Cardiology</i> , 2008, 31, 11-11.	1.8	2
117	The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 359-365.	3.8	32
118	Aspirin "resistance": role of pre-existent platelet reactivity and correlation between tests. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 2035-2044.	3.8	77
119	Effects of physiologic agonists on canine whole blood flow cytometry assays of leukocyte "platelet aggregation and platelet activation. <i>Veterinary Immunology and Immunopathology</i> , 2008, 123, 345-352.	1.2	19
120	Effect of adenosine A2 receptor stimulation on platelet activation "aggregation: Differences between canine and human models. <i>Thrombosis Research</i> , 2008, 121, 689-698.	1.7	30
121	Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children. <i>Circulation</i> , 2008, 117, 553-559.	1.6	135
122	Antithrombotic Therapy in Neonates and Children. <i>Chest</i> , 2008, 133, 887S-968S.	0.8	602
123	P2Y ₁₂ Antagonism. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, s33-8.	2.4	91
124	Platelet Antistaphylococcal Responses Occur through P2X ₁ and P2Y ₁₂ Receptor-Induced Activation and Kinocidin Release. <i>Infection and Immunity</i> , 2008, 76, 5706-5713.	2.2	47
125	Response to Letter Regarding Article, "Dosing of Clopidogrel for Platelet Inhibition in Infants and Young Children: Primary Results of the Platelet Inhibition in Children On cLOpidogrel (PICOLO) Trial". <i>Circulation</i> , 2008, 118, .	1.6	0
126	The active metabolite of prasugrel inhibits adenosine diphosphate- and collagen-stimulated platelet procoagulant activities. <i>Journal of Thrombosis and Haemostasis</i> , 2008, 6, 359-365.	3.8	34

#	ARTICLE	IF	CITATIONS
127	Monitoring Antiplatelet Therapy. , 2008, , 125-158.		0
128	Laboratory assessment of platelet function and coagulation. , 2008, , 19-31.		0
129	Thrombus Formation. , 2008, , 3-13.		1
130	Response to Letter Regarding Article, "Residual Arachidonic Acid-Induced Platelet Activation via an Adenosine Diphosphate-Dependent but Cyclooxygenase-1- and Cyclooxygenase-2-Independent Pathway: A 700-Patient Study of Aspirin Resistance"; Circulation, 2007, 115, .	1.6	0
131	Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention. Circulation, 2007, 116, 2923-2932.	1.6	831
132	Platelets and leukocytes: aggregate knowledge. Blood, 2007, 110, 794-795.	1.4	7
133	Measuring antiplatelet drug effects in the laboratory. Thrombosis Research, 2007, 120, 323-336.	1.7	171
134	Cystic fibrosis heterozygotes do not have increased platelet activation. Thrombosis Research, 2007, 121, 159-162.	1.7	4
135	Platelet Function Monitoring in Patients With Coronary Artery Disease. Journal of the American College of Cardiology, 2007, 50, 1822-1834.	2.8	437
136	The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thrombosis and Haemostasis, 2007, 98, 192-200.	3.4	51
137	The Clinical Approach to Disorders of Platelet Number and Function. , 2007, , 825-830.		1
138	Evidence that pre-existent variability in platelet response to ADP accounts for "clopidogrel resistance". Journal of Thrombosis and Haemostasis, 2007, 5, 75-81.	3.8	96
139	Indices of platelet activation and the stability of coronary artery disease. Journal of Thrombosis and Haemostasis, 2007, 5, 761-765.	3.8	99
140	Evidence that pre-existent variability in platelet response to ADP accounts for "clopidogrel resistance": reply to a rebuttal. Journal of Thrombosis and Haemostasis, 2007, 5, 1089-1090.	3.8	0
141	In Vivo Effects of Eltrombopag on Human Platelet Function.. Blood, 2007, 110, 1301-1301.	1.4	6
142	The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thrombosis and Haemostasis, 2007, 98, 192-200.	3.4	19
143	Antiplatelet therapy in children. Thrombosis Research, 2006, 118, 75-83.	1.7	43
144	Preconditioning ischemia attenuates molecular indices of platelet activation-aggregation. Journal of Thrombosis and Haemostasis, 2006, 4, 2670-2677.	3.8	37

#	ARTICLE	IF	CITATIONS
145	Frequency of Aspirin Resistance in a Community Hospital. American Journal of Cardiology, 2006, 98, 577-579.	1.6	60
146	Current Options in Platelet Function Testing. American Journal of Cardiology, 2006, 98, S4-S10.	1.6	172
147	Resistance to antiplatelet drugs. Country Review Ukraine, 2006, 8, G53-G58.	0.8	34
148	Aspirin Resistance. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 5-9.	0.3	6
149	Evaluation Of Platelet Function By Flow Cytometry. Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research, 2006, 35, 67-82.	0.3	82
150	Arterial Ischemic Stroke in Children. Circulation, 2006, 114, 2094-2095.	1.6	1
151	Residual Arachidonic Acid-Induced Platelet Activation via an Adenosine Diphosphate-Dependent but Cyclooxygenase-1 and Cyclooxygenase-2-Independent Pathway. Circulation, 2006, 113, 2888-2896.	1.6	288
152	The Inflammatory Role of Platelets in Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 483-490.	5.6	81
153	<i>DESIGNING FOR THE HOMELESS: ARCHITECTURE THAT WORKS</i> . Sam Davis. Art Documentation, 2005, 24, 63-64.	0.1	0
154	Platelet activation in cystic fibrosis. Blood, 2005, 105, 4635-4641.	1.4	111
155	GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 2005, 3, 312-320.	3.8	55
156	Aspirin resistance: position paper of the Working Group on Aspirin Resistance. Journal of Thrombosis and Haemostasis, 2005, 3, 1309-1311.	3.8	315
157	Effects of platelet binding on whole blood flow cytometry assays of monocyte and neutrophil procoagulant activity. Journal of Thrombosis and Haemostasis, 2005, 3, 2563-2570.	3.8	79
158	Survival of baboon biotin-X-N-hydroxysuccinimide and ¹¹¹ In-oxine-labelled autologous fresh and lyophilized reconstituted platelets. Vox Sanguinis, 2005, 88, 122-129.	1.5	30
159	Aspirin Resistance: Detection, Mechanisms and Clinical Implications. Current Cardiology Reviews, 2005, 1, 203-211.	1.5	2
160	Markers of Platelet Activation and Granule Secretion. , 2005, , 301-314.		3
161	Platelet function testing in cardiovascular diseases. Hematology, 2005, 10, 132-137.	1.5	7
162	Noncompliance in cardiovascular clinical trials. American Heart Journal, 2005, 150, 882-886.	2.7	31

#	ARTICLE	IF	CITATIONS
163	Clopidogrel. <i>Journal of the American College of Cardiology</i> , 2005, 46, 646-647.	2.8	12
164	Detection and Mechanisms of GPIIb-IIIa Antagonist Induced Thrombocytopenia: Role for Antibody Induced Platelet Activation.. <i>Blood</i> , 2005, 106, 1654-1654.	1.4	0
165	Application of Flow Cytometry to Platelet Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2004, 30, 501-511.	2.7	111
166	Platelet Function Testing in Cardiovascular Diseases. <i>Circulation</i> , 2004, 110, e489-93.	1.6	267
167	Antithrombotic Therapy in Children*. <i>Chest</i> , 2004, 126, 645S-687S.	0.8	370
168	In vitro testing of fresh and lyophilized reconstituted human and baboon platelets. <i>Transfusion</i> , 2004, 44, 1505-1512.	1.6	18
169	GPIIb/IIIa Inhibitor-Induced Dethrombosis. <i>Journal of Thrombosis and Thrombolysis</i> , 2004, 18, 11-17.	2.1	10
170	Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization. <i>Journal of the American College of Cardiology</i> , 2004, 43, 2319-2325.	2.8	120
171	Patients with Coronary Artery Disease Have an Increased Incidence of Aspirin Resistance: Association of PFA-100 Closure Time with Clinical Findings.. <i>Blood</i> , 2004, 104, 1859-1859.	1.4	10
172	How Platelets Work: Platelet Function and Dysfunction. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 16, 7-12.	2.1	46
173	Platelet Inhibitor Therapy: Mechanisms of Action and Clinical Use. <i>Journal of Thrombosis and Thrombolysis</i> , 2003, 16, 13-15.	2.1	2
174	Combined effects of mild hypothermia and glycoprotein IIb/IIIa antagonists on platelet-platelet and leukocyte-platelet aggregation. <i>American Journal of Cardiology</i> , 2003, 92, 1099-1101.	1.6	36
175	Platelet FcγRIIA HIS131ARG polymorphism and platelet function: antibodies to platelet-bound fibrinogen induce platelet activation. <i>Journal of Thrombosis and Haemostasis</i> , 2003, 1, 355-362.	3.8	17
176	The cleaved peptide of PAR1 is a more potent stimulant of platelet-endothelial cell adhesion than is thrombin. <i>Journal of Vascular Surgery</i> , 2003, 37, 440-445.	1.1	7
177	Quantification of abciximab-induced platelet inhibition is assay dependent: A comparative study in patients undergoing percutaneous coronary intervention. <i>American Heart Journal</i> , 2003, 145, M1-M6.	2.7	7
178	Whole Blood Analysis of Leukocyte-Platelet Aggregates. <i>Current Protocols in Cytometry</i> , 2003, 24, Unit 6.15.	3.7	28
179	Neonatal Platelet Function. <i>Seminars in Thrombosis and Hemostasis</i> , 2003, 29, 363-372.	2.7	105
180	Two novel mutations in the α IIb calcium-binding domains identify hydrophobic regions essential for α IIb β 3 biogenesis. <i>Blood</i> , 2003, 101, 2268-2276.	1.4	36

#	ARTICLE	IF	CITATIONS
181	Spirochete-platelet attachment and thrombocytopenia in murine relapsing fever borreliosis. <i>Blood</i> , 2003, 102, 2843-2850.	1.4	41
182	An Additional Mechanism of Action of Abciximab: Dispersal of Newly Formed Platelet Aggregates. <i>Thrombosis and Haemostasis</i> , 2002, 87, 1020-1025.	3.4	78
183	Immunophenotypic Analysis of Platelets. <i>Current Protocols in Cytometry</i> , 2002, 19, Unit 6.10.	3.7	22
184	The ultegra rapid platelet-function assay: Comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy. <i>American Heart Journal</i> , 2002, 143, 602-611.	2.7	56
185	Flow cytometric analysis of platelet function. , 2002, , 485-498.		6
186	Platelet-monocyte aggregates in patients with chronic venous insufficiency remain elevated following correction of reflux. <i>Vascular</i> , 2002, 10, 464-9.	0.5	9
187	Circulating monocyte-platelet aggregates are an early marker of acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2001, 38, 1002-1006.	2.8	365
188	Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. <i>American Heart Journal</i> , 2001, 142, 790-798.	2.7	50
189	Serial Determinations of Platelet Counts in Mice by Flow Cytometry. <i>Thrombosis and Haemostasis</i> , 2001, 86, 668-671.	3.4	37
190	Antithrombotic Therapy in Children. <i>Chest</i> , 2001, 119, 344S-370S.	0.8	240
191	Regulation of P-selectin binding to the neutrophil P-selectin counter-receptor P-selectin glycoprotein ligand-1 by neutrophil elastase and cathepsin G. <i>Blood</i> , 2001, 98, 1440-1447.	1.4	69
192	Platelet activation by a relapsing fever spirochaete results in enhanced bacterium-platelet interaction via integrin alphaIIb beta3 activation. <i>Molecular Microbiology</i> , 2001, 39, 330-341.	2.5	36
193	Laser scanning cytometry: A novel method for the detection of platelet-endothelial cell adhesion. <i>Cytometry</i> , 2001, 43, 308-313.	1.8	6
194	Circulating Monocyte-Platelet Aggregates Are a More Sensitive Marker of In Vivo Platelet Activation Than Platelet Surface P-Selectin. <i>Circulation</i> , 2001, 104, 1533-1537.	1.6	652
195	Dissociation of Glycoprotein IIb/IIIa Antagonists From Platelets Does Not Result in Fibrinogen Binding or Platelet Aggregation. <i>Circulation</i> , 2001, 104, 1374-1379.	1.6	42
196	Platelet and Platelet-derived Microparticle Surface Factor V/Va Binding in Whole Blood: Differences between Neonates and Adults. <i>Thrombosis and Haemostasis</i> , 2000, 84, 689-694.	3.4	51
197	Antithrombotic therapy in the cardiac catheterization laboratory: Focus on antiplatelet agents. <i>Current Cardiology Reports</i> , 2000, 2, 386-394.	2.9	9
198	GP1Ib-IIIa Antagonist-induced Reduction in Platelet Surface Factor V/Va Binding and Phosphatidylserine Expression in Whole Blood. <i>Thrombosis and Haemostasis</i> , 2000, 84, 492-498.	3.4	60

#	ARTICLE	IF	CITATIONS
199	The Cleaved Peptide of PAR1 Results in a Redistribution of the Platelet Surface GPIb-IX-V Complex to the Surface-Connected Canalicular System. <i>Thrombosis and Haemostasis</i> , 2000, 84, 897-903.	3.4	36
200	Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 222-240.	2.5	19
201	Platelet GP IIIa Pl ^A Polymorphisms Display Different Sensitivities to Agonists. <i>Circulation</i> , 2000, 101, 1013-1018.	1.6	319
202	Evaluation of Platelet Function by Flow Cytometry. <i>Methods</i> , 2000, 21, 259-270.	3.8	224
203	Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 222-240.	2.5	9
204	Platelets: New Understanding of Platelet Glycoproteins and Their Role in Disease. <i>Hematology American Society of Hematology Education Program</i> , 2000, 2000, 222-240.	2.5	1
205	Nitric oxide insufficiency and arterial thrombosis. <i>Transactions of the American Clinical and Climatological Association</i> , 2000, 111, 158-63.	0.5	7
206	Flow cytometric analysis of platelets. <i>Vox Sanguinis</i> , 2000, 78 Suppl 2, 137-42.	1.5	0
207	GPIIb-IIIa antagonist-induced reduction in platelet surface factor V/Va binding and phosphatidylserine expression in whole blood. <i>Thrombosis and Haemostasis</i> , 2000, 84, 492-8.	3.4	13
208	Platelet and platelet-derived microparticle surface factor V/Va binding in whole blood: differences between neonates and adults. <i>Thrombosis and Haemostasis</i> , 2000, 84, 689-94.	3.4	12
209	Nitric Oxide Inhibits Thrombin Receptor-activating Peptide-induced Phosphoinositide 3-Kinase Activity in Human Platelets. <i>Journal of Biological Chemistry</i> , 1999, 274, 14368-14375.	3.4	80
210	Plasma Glutathione Peroxidase Deficiency and Platelet Insensitivity to Nitric Oxide in Children With Familial Stroke. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999, 19, 2017-2023.	2.4	80
211	The effects of aspirin and hypothermia on platelet function in vivo. <i>British Journal of Haematology</i> , 1999, 104, 64-68.	2.5	42
212	Platelet surface p-selectin, platelet-granulocyte heterotypic aggregates, and plasma-soluble p-selectin during plateletpheresis. <i>Transfusion</i> , 1999, 39, 735-741.	1.6	17
213	Fresh, liquid-preserved, and cryopreserved platelets: adhesive surface receptors and membrane procoagulant activity. <i>Transfusion</i> , 1999, 39, 880-888.	1.6	70
214	Comparison of the effects of transfusions of cryopreserved and liquid-preserved platelets on hemostasis and blood loss after cardiopulmonary bypass. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 1999, 117, 172-184.	0.8	138
215	Chronic venous insufficiency is associated with increased platelet and monocyte activation and aggregation. <i>Journal of Vascular Surgery</i> , 1999, 30, 844-853.	1.1	47
216	Laboratory markers of platelet activation and their clinical significance. <i>Current Opinion in Hematology</i> , 1999, 6, 342-348.	2.5	120

#	ARTICLE	IF	CITATIONS
217	Elevated plasma glycofibrinogen levels and decreased ristocetin-induced platelet agglutination in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 1998, 32, 132-138.	1.9	16
218	Guidelines for antithrombotic therapy in pediatric patients. <i>Journal of Pediatrics</i> , 1998, 132, 575-588.	1.8	131
219	Increased Platelet Reactivity and Circulating Monocyte-Platelet Aggregates in Patients With Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 1998, 31, 352-358.	2.8	456
220	Patients with venous stasis ulceration have increased monocyte-platelet aggregation. <i>Journal of Vascular Surgery</i> , 1998, 27, 1109-1116.	1.1	36
221	Platelet Function in the Newborn. <i>Seminars in Thrombosis and Hemostasis</i> , 1998, 24, 507-512.	2.7	65
222	Antithrombotic Therapy in Children. <i>Chest</i> , 1998, 114, 748S-769S.	0.8	179
223	The cleaved peptide of the thrombin receptor is a strong platelet agonist. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 3082-3087.	7.1	63
224	European Working Group on Clinical Cell Analysis: Consensus Protocol for the Flow Cytometric Characterisation of Platelet Function. <i>Thrombosis and Haemostasis</i> , 1998, 79, 885-896.	3.4	337
225	Flow cytometric assessment of glycoprotein movements in platelets. <i>Platelets</i> , 1997, 8, 105-115.	2.3	4
226	Platelet Hyporeactivity in Very Low Birth Weight Neonates. <i>Thrombosis and Haemostasis</i> , 1997, 77, 1002-1007.	3.4	111
227	The Prevention and Treatment of Thromboembolic Disease in Children: A Need for Thrombophilia Programs. <i>The American Journal of Pediatric Hematology/Oncology</i> , 1997, 19, 7-22.	1.3	21
228	Nitric oxide released from activated platelets inhibits platelet recruitment.. <i>Journal of Clinical Investigation</i> , 1997, 100, 350-356.	8.2	341
229	Platelets are degranulated by some, but not all, contrast media. <i>Academic Radiology</i> , 1996, 3, S328-S330.	2.5	4
230	Variability of platelet degranulation by different contrast media. <i>Academic Radiology</i> , 1996, 3, S485-S487.	2.5	16
231	SPECIAL ARTICLE. <i>Journal of Surgical Research</i> , 1996, 61, 543-548.	1.6	52
232	Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis.. <i>Journal of Clinical Investigation</i> , 1996, 97, 979-987.	8.2	147
233	Effect of heparin on fibrinolytic activity and platelet function in vivo. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1996, 271, H528-H534.	3.2	12
234	Effects of nitric oxide/EDRF on platelet surface glycoproteins. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1996, 270, H1640-H1648.	3.2	40

#	ARTICLE	IF	CITATIONS
235	In vivo tracking of platelets: circulating degranulated platelets rapidly lose surface P-selectin but continue to circulate and function.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 11877-11882.	7.1	519
236	Reduction of bleeding after heart operations through the prophylactic use of epsilon-aminocaproic acid. Journal of Thoracic and Cardiovascular Surgery, 1996, 112, 1098-1107.	0.8	111
237	The platelet surface expression of glycoprotein V is regulated by two independent mechanisms: proteolysis and a reversible cytoskeletal-mediated redistribution to the surface-connected canalicular system. Blood, 1996, 87, 1396-408.	1.4	3
238	Flow cytometry: a clinical test of platelet function. Blood, 1996, 87, 4925-36.	1.4	86
239	Antithrombotic Therapy in Children. Chest, 1995, 108, 506S-522S.	0.8	80
240	Platelet Degranulation Induced by Some Contrast Media is Independent of Their Nonionic vs Ionic Nature. Acta Radiologica, 1995, 36, 182-184.	1.1	7
241	A Morphologic Question. New England Journal of Medicine, 1995, 333, 1051-1051.	27.0	1
242	Fibrinolysis Inhibits Shear Stress-Induced Platelet Aggregation. Circulation, 1995, 92, 1399-1407.	1.6	24
243	Platelet activation results in a redistribution of glycoprotein IV (CD36).. Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994, 14, 1193-1201.	3.9	30
244	Human neutrophil cathepsin G is a potent platelet activator. Journal of Vascular Surgery, 1994, 19, 306-320.	1.1	69
245	Effects of Contrast Media on Platelet Activation Using Flowing Whole Blood Aggregometry and Flow Cytometry of Platelet Membrane Glycoproteins. Investigative Radiology, 1994, 29, S198-S200.	6.2	2
246	Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cytometry. Blood Coagulation and Fibrinolysis, 1994, 5, 121-132.	1.0	100
247	Reversible Inhibition of Human Platelet Activation by Hypothermia In Vivo and In Vitro. Thrombosis and Haemostasis, 1994, 71, 633-640.	3.4	338
248	Neonatal Platelets Are Less Reactive than Adult Platelets to Physiological Agonists in Whole Blood. Thrombosis and Haemostasis, 1994, 72, 957-963.	3.4	128
249	Neutrophil cathepsin G modulates the platelet surface expression of the glycoprotein (GP) Ib-IX complex by proteolysis of the von Willebrand factor binding site on GPIb alpha and by a cytoskeletal-mediated redistribution of the remainder of the complex. Blood, 1994, 84, 158-68.	1.4	7
250	Reversible inhibition of human platelet activation by hypothermia in vivo and in vitro. Thrombosis and Haemostasis, 1994, 71, 633-40.	3.4	90
251	Neonatal platelets are less reactive than adult platelets to physiological agonists in whole blood. Thrombosis and Haemostasis, 1994, 72, 957-63.	3.4	27
252	The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible. Blood, 1994, 83, 3562-73.	1.4	5

#	ARTICLE	IF	CITATIONS
253	Effect of strenuous exercise on platelet activation state and reactivity.. Circulation, 1993, 88, 1502-1511.	1.6	312
254	Nonionic Contrast Media Procoagulants or Clotting Innocents?. Investigative Radiology, 1993, 28, 21-24.	6.2	32
255	Aprotinin reduces cardiopulmonary bypass-induced blood loss and inhibits fibrinolysis without influencing platelets. British Journal of Haematology, 1993, 85, 533-541.	2.5	60
256	Thrombin-Induced Down-Regulation of the Platelet Membrane Glycoprotein Ib-IX Complex. Seminars in Thrombosis and Hemostasis, 1992, 18, 18-27.	2.7	46
257	High-dose heparin suppresses platelet alpha granule secretion. Journal of Vascular Surgery, 1992, 15, 1000-1009.	1.1	27
258	Precoating expanded polytetrafluoroethylene grafts alters production of endothelial cell[mdash]derived thrombomodulators. Journal of Vascular Surgery, 1992, 15, 1010-1017.	1.1	23
259	Platelet glycogen synthase: Further characterization and effect of insulin. Thrombosis Research, 1991, 63, 427-432.	1.7	2
260	Thrombocytopenia associated with environmental exposure to polyurethane. American Journal of Hematology, 1991, 38, 145-146.	4.1	2
261	Pathomechanism of Defective Hemostasis During and After Extracorporeal Circulation: The Role of Platelets. , 1991, , 16-26.		5
262	Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or an in vivo wound. Blood, 1991, 77, 770-9.	1.4	31
263	Glycoprotein Ib (GPIb)-dependent and GPIb-independent pathways of thrombin-induced platelet activation. Blood, 1991, 77, 1740-8.	1.4	9
264	Effect of in vivo infusion of recombinant tissue-type plasminogen activator on platelet glycoprotein Ib. Thrombosis Research, 1990, 60, 421-424.	1.7	6
265	Plasmin-induced redistribution of platelet glycoprotein Ib. Blood, 1990, 76, 2005-10.	1.4	10
266	Chemotherapy-Induced Painful Acral Erythema in Childhood. Journal of Pediatric Hematology/Oncology, 1989, 11, 44-45.	0.6	13
267	Platelet storage results in a redistribution of glycoprotein Ib molecules. Evidence for a large intraplatelet pool of glycoprotein Ib.. Journal of Clinical Investigation, 1988, 81, 1734-1740.	8.2	97
268	Flow cytometric detection of distinct subpopulations of platelets in individual patients. Progress in Clinical and Biological Research, 1988, 283, 131-6.	0.2	1
269	Thrombin-induced changes in platelet membrane glycoproteins. Progress in Clinical and Biological Research, 1988, 283, 159-62.	0.2	0
270	Transient Neurological Disorder Associated with Transient Erythroblastopenia of Childhood. Journal of Pediatric Hematology/Oncology, 1987, 9, 161-163.	0.6	6

#	ARTICLE	IF	CITATIONS
271	Flow cytometric analysis of platelet surface glycoproteins: phenotypically distinct subpopulations of platelets in children with chronic myeloid leukemia. <i>Translational Research</i> , 1987, 110, 346-54.	2.3	34
272	Thrombin-induced changes in platelet membrane glycoproteins Ib, IX, and IIb-IIIa complex. <i>Blood</i> , 1987, 70, 1673-8.	1.4	11
273	Partial characterization of a binding site for von Willebrand factor on glycofalin. <i>Blood</i> , 1986, 67, 19-26.	1.4	6
274	Plasmin effect on platelet glycoprotein Ib-von Willebrand factor interactions. <i>Blood</i> , 1985, 65, 32-40.	1.4	30
275	Evaluation of platelet glycoprotein Ib by fluorescence flow cytometry. <i>Blood</i> , 1985, 66, 423-7.	1.4	5
276	Haemolytic anaemia associated with acquired toxoplasmosis. <i>Journal of Paediatrics and Child Health</i> , 1984, 20, 333-335.	0.8	4
277	The blood film in meningococcal disease. <i>Medical Journal of Australia</i> , 1983, 1, 502-502.	1.7	0
278	Inheritance of Diamond-Blackfan anaemia. <i>Medical Journal of Australia</i> , 1982, 2, 409-410.	1.7	5
279	Partial deletion of the β -globin structural gene in human β -thalassaemia. <i>Nature</i> , 1980, 286, 538-540.	27.8	79
280	Laboratory Assessment of Platelet Function and the Effects of Antiplatelet Agents. , 0, , 15-29.		0
281	Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 study. <i>Blood</i> , 0, , .	1.4	5